CAS Number115436-72-1
SynonymsT6NJ C1XQPQQO&PQQO &&Mono Na salt; Actonel; Natriumhydrogen-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonat; Risedronic acid monosodium salt; sodium hydrogen (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonate; Benet; hydrogène (1-hydroxy-1-phosphono-2-pyridin-3-yléthyl)phosphonate de sodium; Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, sodium salt (1:1); MFCD01706268; phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, monosodium salt; Sodium risedronate; sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate; P,P'-[1-Hydroxy-2-(3-pyridonyl)ethylidene]bis-phosphonic acid sodium salt; Sodium hydrogen [1-hydroxy-1-phosphono-2-(3-pyridinyl)ethyl]phosphonate; Risedronic acid sodium salt; sodium hydrogen-1-hydroxy-1-phosphono-2-(pyridin-3-yl)et
Molecular FormulaC7H10NNaO7P2
Molecular Weight350.13
Purity98%
Boiling Point692.3ºC at 760 mmHg
Melting Point252-262°C
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 115436-72-1 |
| Catalog No. | 2A-9012314 |
| Chinese Name | 利赛膦酸钠 |
| Synonyms | T6NJ C1XQPQQO&PQQO &&Mono Na salt; Actonel; Natriumhydrogen-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonat; Risedronic acid monosodium salt; sodium hydrogen (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonate; Benet; hydrogène (1-hydroxy-1-phosphono-2-pyridin-3-yléthyl)phosphonate de sodium; Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, sodium salt (1:1); MFCD01706268; phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, monosodium salt; Sodium risedronate; sodium hydrogen [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonate; P,P'-[1-Hydroxy-2-(3-pyridonyl)ethylidene]bis-phosphonic acid sodium salt; Sodium hydrogen [1-hydroxy-1-phosphono-2-(3-pyridinyl)ethyl]phosphonate; Risedronic acid sodium salt; sodium hydrogen-1-hydroxy-1-phosphono-2-(pyridin-3-yl)et |
| Molecular Formula | C7H10NNaO7P2 |
| Molecular Weight | 350.13 |
| Purity | 98 |
| Boiling Point | 692.3ºC at 760 mmHg |
| Melting Point | 252-262°C |
| Appearance | powder |
| Storage Condition | Store at RT |
| Application | Risedronate sodium is a bisphosphonate that inhibits osteoclast-mediated bone resorption. |
| MDL Number | MFCD01706268 |
| SMILES | OP(C(P(O)([O-])=O)(O)CC1=CC=CN=C1)(O)=O.[Na+] |
| InChI | 1S/2C7H11NO7P2.2Na.5H2O/c2*9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;;;;;;;/h2*1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);;;5*1H2/q;;2*+1;;;;;/p-2 |
| InChI Key | HYFDYHPNTXOPPO-UHFFFAOYSA-L |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| Hazard Symbols | Transport |
| MSDS | msds/12314_1_115436_72_1.pdf |
| Bioactivity | Risedronate sodium is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: Risedronate sodium, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate sodium is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy [1].The administration of 20 and 25 mg/kg risedronate sodium for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate sodium, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls [2].Clinical indications: Bone resorption; Male osteoporosis; Osteogenesis imperfecta; Osteoporosis; Pagets bone disease Toxicity: abdominal pain; anxiety, back pain; belching, bladder irritation; bone disorders and pain; bronchitis; bursitis; cataracts; chest pain; colitis; constipation; depression; diarrhea; difficulty breathing Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Others References [1]. Giljevic Z, et al. Treatment of osteoporosis by risedronate-- speed, efficacy and safety. Reumatizam. 2006;53(2):66-71. [2]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. Chemical & Physical Properties Boiling Point 692.3ºC at 760 mmHg Melting Point 252-262°C Molecular Formula C7H10NNaO7P2 Molecular Weight 305.094 Flash Point 372.5ºC Exact Mass 304.983032 PSA 170.63000 LogP 0.06380 Vapour Pressure 4.03E-20mmHg at 25°C InChIKey DRFDPXKCEWYIAW-UHFFFAOYSA-M SMILES O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+] Storage condition Store at RT |
| Use of | Properties Articles32 Name Sodium risedronate Synonym More Synonyms Sodium risedronate Biological Activity Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Others References [1]. Giljevic Z, et al. Treatment of osteoporosis by risedronate-- speed, efficacy and safety. Reumatizam. 2006;53(2):66-71. [2]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31. Chemical & Physical Properties Molecular Formula C7H10NNaO7P2 Exact Mass 304.983032 PSA 170.63000 LogP 0.06380 InChIKey DRFDPXKCEWYIAW-UHFFFAOYSA-M Storage condition Store at RT |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Ramiprilat | 87269-97-4 | 2A-9012262 |
| Ranitidine | 66357-35-5 | 2A-9012267 |
| Remifentanil | 132875-61-7 | 2A-9012280 |
| Ribavirin | 36791-04-5 | 2A-9012297 |
| Rifabutin | 72559-06-9 | 2A-0201665 |
| Ritonavir | 155213-67-5 | 2A-9012321 |
| Rivastigmine | 123441-03-2 | 2A-9012322 |
| Rivastigmine tartrate | 129101-54-8 | 2A-9012323 |
| Rofecoxib | 162011-90-7 | 2A-9012330 |
| Rolitetracycline | 751-97-3 | 2A-9012333 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS